No Added Benefit of AZD8931 in Combination With Endocrine Therapy in Advanced Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Breast Cancer Research and Treatment
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Inhibition of EGFR, HER2, and HER3 Signaling With AZD8931 in Combination With Anastrozole as an Anticancer Approach: Phase II Randomized Study in Women With Endocrine-Therapy-Naïve Advanced Breast Cancer
Breast Cancer Res Treat 2016 Sep 21;[EPub Ahead of Print], S Johnston, M Basik, R Hegg, W Lausoontornsiri, L Grzeda, M Clemons, L Dreosti, H Mann, M Stuart, M CristofanilliFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.